Effects of Stat3 antisense oligodeoxynucleotide on growth of subcutaneous transplanted tumors in human Hep-2 cell tumor-bearing BALB/c nude mouse
-
摘要: 目的: 研究Stat3反义寡核苷酸(AS3)对荷人喉癌 Hep-2裸鼠的抑瘤作用,探求AS3对喉癌的治疗价值。方法: 取对数生长期的人喉癌 Hep-2 细胞接种于BALB/c 小鼠皮下,建立荷人喉癌 Hep-2小鼠模型。随机分为空白组、对照组和不同浓度的AS3(1组、2组、3组、4组),然后腹腔内给药,1次/d,连续4周,每周2次测量体重,并记录肿瘤长径、短径,4 周后各组小鼠称体重,剥离皮下移植瘤,称瘤重、计算抑瘤率。结果: AS3对人喉癌 Hep-2裸鼠皮下移植瘤具有明显抑制肿瘤生长的作用,各剂量间有量效关系。各组抑瘤率明显高于对照组(P<0.01)。结论: AS3可抑制人喉癌 Hep-2细胞BALB/c裸鼠皮下移植瘤的生长,可能对人喉癌的治疗有一定作用。
-
关键词:
- Stat3反义寡核苷酸 /
- 喉癌 /
- 裸鼠 /
- 皮下移植瘤
Abstract: Objective: To explore the anti-tumor effect of Stat3 antisense oligodeoxynucleotide on human Hep-2 cell tumor-bearing BALB/c nude mouse, to study the therapeutic value of Stat3 antisense oligodeoxynucleotide on laryngeal cancer.Method: Hep-2 cells from human laryngeal carcinoma in logarithmic phase were inoculated subcutaneously into BALB/c mice to establish a model of human Hep-2 cell tumor-bearing BALB/c mice. They were divided into blank group, control group and different concentrations of AS3 groups(1 group, 2 group, 3 group, 4 group), and then intraperitoneally administered once a day for 4 weeks, measuring body weight twice a week, and the long and short diameters of the tumors were recorded. After 4 weeks, the mice in each group were weighted. The subcutaneous transplanted tumors were dissected, weighted, and inhibitory rate(IR) was obtained.Result: Stat3 antisense oligodeoxynucleotide can obviously inhibited the growth of human Hep-2 cell tumor-bearing BALB/c mice with the concentration of antisense oligodeoxynucleotide heightened. The IR in different concentration AS3 groups was obviously higher than that in the control group(P<0.01).Conclusion: Stat3 antisense oligodeoxynucleotide can obviously inhibit the growth of subcutaneous transplanted tumors in human Hep-2 cell tumor-bearing BALB/c mice, and may have therapeutical effect on laryngeal cancer. -
-
[1] SIVEEN K S, SIKKA S, SURANA R, et al.Targeting the STAT3 signaling pathway in cancer:role of synthetic and natural inhibitors[J].Biochim Biophys Acta, 2014, 1845:136-154.
[2] TIMME S, IHDE S, FICHTER C D, et al.STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas[J].Oncogene, 2014, 33:3256-3266.
[3] BROMBERGJ F, WRZESZCZYNSKA M H, DEV GAN G, et al.Stat3 as an oncogene[J].Cell, 1999, 98:295-303.
[4] 吕海丽, 张秋航, 严波.Stat3反义寡脱氧核苷酸在体外诱导喉癌细胞凋亡[J].临床耳鼻咽喉头颈外科杂志, 2008, 22 (21):968-971.
[5] 吕海丽, 张秋航, 严波.Stat3反义核苷酸通过调节凋亡相关因子诱导喉癌细胞凋亡[J].临床耳鼻咽喉头颈外科杂志, 2010, 24 (4):155-157.
[6] MASSA S T, PETERS N O, FRANCO J, et al.Survival after refusal of surgical treatment for locally advanced laryngeal cancer[J].Oral Oncol, 2017, 71:34-40.
[7] GROVER S, SWISHER-MCCLURE S, MITRA N, et al.Total laryngectomy versus larynxpreservation for t4a larynx cancer:patterns of care and survival outcomes[J].Int J Radiat Oncol Biol Phys, 2015, 92:594-601.
[8] 彭永华, 杨文飞, 卢绍伟, 等.miRNA在喉癌中作用机制的研究进展[J].临床耳鼻咽喉头颈外科杂志, 2017, 31 (14):1134-1139.
[9] 冶娟, 解静.STIM1RNA干扰对人喉癌细胞增殖和凋亡的影响[J].临床耳鼻咽喉头颈外科杂志, 2017, 31 (11):844-848.
[10] LUTTICKEN C, WEGENKA U M, YUAN J, et al.Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6signal transducer[J].Science, 1994, 263:89-92.
[11] WANG Y, SHEN Y, WANG S, et al.The role of STAT3 in leading the crosstalk between human cancers and the immune system[J].Cancer Lett, 2018, 415:117-128.
[12] 杨彦忠, 唐坚.靶向STAT3信号通路抗肿瘤治疗策略的研究进展[J], 中国肿瘤生物治疗杂志, 2017, 24 (12):1436-1442.
[13] CHAI E Z P, SHANMUGAM M K, ARFUSO F, et al.Targeting transcription factor STAT3 for cancer prevention and therapy[J].Pharmacol Therapeut, 2016, 216:86-97.
[14] 吕海丽, 张秋航, 严波.反义Stat3基因诱导喉癌细胞凋亡的线粒体机制探讨[J].临床耳鼻咽喉头颈外科杂志, 2012, 26 (7):316-318.
[15] HILLMER E J, ZHANG H Y, LI H S, et al.STAT3 signaling in immunity[J].Cytokine Growth Factor Rev.2016, 31:1-15.
[16] HU D, WAN L, CHEN M, et al.Essential role of IL-10/STAT3 in chronic stress-induced immune suppression[J].Brain Behavior Immunity, 2014, 36:118-127.
-
计量
- 文章访问数: 289
- PDF下载数: 165
- 施引文献: 0
下载: